Shares of Oxford BioMedica plc (OTCMKTS:OXBDF) have earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company.
Several research firms have recently issued reports on OXBDF. Zacks Investment Research cut shares of Oxford BioMedica from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. HC Wainwright reissued a “buy” rating on shares of Oxford BioMedica in a report on Wednesday, May 6th. Peel Hunt reissued a “buy” rating on shares of Oxford BioMedica in a report on Tuesday, July 28th. Liberum Capital reissued a “buy” rating on shares of Oxford BioMedica in a report on Tuesday, July 28th. Finally, ValuEngine lowered shares of Oxford BioMedica from a “buy” rating to a “hold” rating in a report on Tuesday, April 14th.
Oxford BioMedica stock opened at $10.73 on Tuesday. Oxford BioMedica has a 1 year low of $4.51 and a 1 year high of $11.75. The firm’s 50 day moving average price is $9.98 and its 200-day moving average price is $8.73.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
See Also: What is a stock portfolio tracker?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.